

Oncotarget
Oncotarget Podcast
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Episodes
Mentioned books

Dec 2, 2022 • 4min
Essential Amino Acids as Diagnostic Biomarkers of Hepatocellular Carcinoma
Researchers Yuji Morine, Tohru Utsunomiya, and Hisami Yamanaka-Okumura discuss using metabolomics to identify potential biomarkers for diagnosing Hepatocellular Carcinoma. Key findings include essential amino acids like leucine, valine, and tryptophan as promising indicators for HCC diagnosis.

Nov 29, 2022 • 4min
Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More
The podcast delves into the intriguing world of Myeloid-Derived Suppressor Cells, discussing their role in cancer immunotherapy, their immunosuppressive activities, and potential manipulation for cancer treatment.

Nov 22, 2022 • 3min
Treasures From Trash In Cancer Research
Researchers explore the overlooked potential of discarded genomic and transcriptomic data from cancer research, uncovering valuable strategies for understanding carcinogenesis and identifying clinical biomarkers.

Nov 22, 2022 • 4min
APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise
Discover how APOE genotype affects cancer survivors' response to exercise intervention, influencing side effects severity and exercise outcomes in female post-treatment survivors, with a focus on lifestyle factors mitigating genetic impact.

Nov 17, 2022 • 4min
Mutation Analysis of Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas
Exploring the impact of CR EBBP mutations on disease-free survival rates in newly diagnosed Germinal Center Aggressive B Cell Lymphomas through mutation analysis on tumor biopsies.

Nov 15, 2022 • 8min
Biomarkers May Predict Neoadjuvant Chemosensitivity in Bladder Cancer
Explore the use of predictive biomarkers in neoadjuvant chemotherapy for bladder cancer, highlighting the importance of personalized treatment. Discover the role of tumor and host biomarkers in identifying patients who will benefit most from chemotherapy. Uncover significant gene sets and molecular pathways that can predict responses to neoadjuvant chemotherapy in muscle invasive bladder cancer.

Nov 10, 2022 • 4min
MK256 a Novel CDK8 Inhibitor With Antitumor Activity in AML Through Downregulation of STAT Pathway
Discover how the CDK8 inhibitor MK256 shows promising antitumor activity in AML by inducing differentiation, inhibiting proliferation, and downregulating the STAT pathway. Researchers from UCSF and Touro University explore the potential of MK256 in treating AML based on their latest study.

Nov 2, 2022 • 3min
Press Release: Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma
Researchers discuss the widespread expression of Nectin-4 in head and neck squamous cell carcinoma, drawing parallels with its role in bladder cancer. Non-smokers and p16 positive cases show higher Nectin-4 expression, with positive tumors exhibiting better survival rates.

Nov 2, 2022 • 5min
New Target Fights Ferroptosis- and Radio-Resistance in Lung Cancers
Learn about the role of FSP1 in mediating resistance to ferroptosis and radiotherapy in lung cancer cells. Explore how FSP1 can be targeted to overcome resistance in KEAP1 mutant lung cancer cells, with implications for radiotherapy and ferroptosis resistance.

Oct 27, 2022 • 3min
Press Release: Oncotarget Is Again On MEDLINE
The podcast discusses the acceptance of Oncotarget into MEDLINE and the importance of biomedical databases like PubMed Central. It highlights the use of controlled vocabulary for indexing and introduces Oncotarget as a reputable oncology journal with international reach.